[go: up one dir, main page]

WO2015017324A1 - Dispositif intervertébral résorbable - Google Patents

Dispositif intervertébral résorbable Download PDF

Info

Publication number
WO2015017324A1
WO2015017324A1 PCT/US2014/048411 US2014048411W WO2015017324A1 WO 2015017324 A1 WO2015017324 A1 WO 2015017324A1 US 2014048411 W US2014048411 W US 2014048411W WO 2015017324 A1 WO2015017324 A1 WO 2015017324A1
Authority
WO
WIPO (PCT)
Prior art keywords
glass
spinal interbody
region
fiber
bioactivity
Prior art date
Application number
PCT/US2014/048411
Other languages
English (en)
Inventor
James Jenq Liu
Casey S. LEWIS
Janet L. KREVOLIN
Original Assignee
Bi02 Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi02 Technologies, Inc. filed Critical Bi02 Technologies, Inc.
Publication of WO2015017324A1 publication Critical patent/WO2015017324A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/10—Ceramics or glasses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
    • A61F2/442—Intervertebral or spinal discs, e.g. resilient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
    • A61F2/4455—Joints for the spine, e.g. vertebrae, spinal discs for the fusion of spinal bodies, e.g. intervertebral fusion of adjacent spinal bodies, e.g. fusion cages
    • A61F2/4465—Joints for the spine, e.g. vertebrae, spinal discs for the fusion of spinal bodies, e.g. intervertebral fusion of adjacent spinal bodies, e.g. fusion cages having a circular or kidney shaped cross-section substantially perpendicular to the axis of the spine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/30004—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis
    • A61F2002/30011—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis differing in porosity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/3006—Properties of materials and coating materials
    • A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30316—The prosthesis having different structural features at different locations within the same prosthesis; Connections between prosthetic parts; Special structural features of bone or joint prostheses not otherwise provided for
    • A61F2002/30535—Special structural features of bone or joint prostheses not otherwise provided for
    • A61F2002/30593—Special structural features of bone or joint prostheses not otherwise provided for hollow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/3094—Designing or manufacturing processes
    • A61F2002/30968—Sintering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00329—Glasses, e.g. bioglass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/38—Materials or treatment for tissue regeneration for reconstruction of the spine, vertebrae or intervertebral discs

Definitions

  • the present invention relates generally to a spinal interbody device such as that used in lumbar or cervical spine fusion procedures, and specifically relates to an interbody device that resorbs over time.
  • Implants are constructed from PEEK, titanium and various other materials and have been designed for insertion through anterior, posterior and lateral approaches.
  • interbody devices require additional fixation to create a fusion across the intended vertebral level.
  • this supplemental fixation can include an anterior plate or pedicle screws and rods inserted posteriorly in a 360 ° procedure.
  • Spinal interbody devices are used in lumbar or cervical spine fusion procedures to treat spondylolisthesis and degenerative disc disease, among others.
  • the device is inserted between adjacent vertebrae, typically with bone graft materials, to maintain the intervertebral space during the intervening period upon which bone fusion occurs between the adjacent vertebrae.
  • spinal interbody devices are suitable for their intended purposes, improvements may be made.
  • the present invention meets the objectives of providing a resorbable spinal interbody device to maintain the intervertebral space and promoting bone tissue ingrowth to effectuate fusion.
  • the resorbable spinal interbody device can be implanted in a lumbar or cervical spine fusion procedure with or without fixation due to the load bearing strength and high rate of bioactivity exhibited by the bioactive glass and glass-ceramic compositions.
  • Fig. 1 shows a first spinal interbody device according to an embodiment of the present invention.
  • Fig. 2 shows a second spinal interbody device according to an
  • Fig. 3 shows a third spinal interbody device according to an embodiment of the present invention.
  • Fig. 4 shows a fourth spinal interbody device according to an
  • Fig. 5 shows a method used to fabricate a porous structural region of the spinal interbody device of the present invention.
  • Fig. 6 depicts the design of an embodiment of the present invention that can be implanted as an intervertebral body in a degenerative disc disease procedure for interbody fusion.
  • the present invention provides a resorbable spinal interbody device that can be implanted between adjacent vertebrae to maintain the
  • the present invention exhibits a controlled resorbabi 1 i ty over time to allow the newly formed bone to gradually assume the spine load. Ultimately once the adjacent vertebrae are fused the interbody device can be fully resorbed by the patient with no harmful side effects.
  • a spinal interbody device 10 is shown for use in fusion of adjacent vertebrae to maintain the intervertebral spacing as bone tissue fuses the adjacent vertebrae.
  • the interbody device 10 has a structural region 100 composed of bioactive glass or bioactive glass-ceramic that maintains the intervertebral space once implanted and can provide load bearing strength.
  • Glass-ceramic materials exhibit properties of increased strength, toughness, thermal stability, machi nabi 1 i ty over amorphous glass materials.
  • a glass-ceramic biomaterial can be designed to exhibit specific rates of dissolution and resorption in vivo.
  • wollastonite in a bioactive glass matrix as a glass-ceramic composition can exhibit bioactivity and bioresorption when implanted in living tissue.
  • the present invention relates to the formation of glass-ceramic compositions while retaining a porous, osteostimulative mi crostructure .
  • the structural region 100 of the interbody device of the present invention can be fabricated using fibers as a raw material that create a bioactive glass-ceramic composition that has a substantially uniform glass- ceramic composition throughout the porous structure. In this way a bioactive and resorbable device can be fabricated with increased strength and
  • the fibers can be composed of a material that is a precursor to the glass-ceramic material , and in an embodiment the fiber is a silica calcium phosphate glass.
  • the term "fiber” as used herein is meant to describe a filament or elongated member in a continuous or discontinuous form having an aspect ratio greater than one, and formed from a fiber-forming process such as drawn, spun, blown, or other similar process typically used in the formation of fibrous materials or other high aspect-ratio materials.
  • Bioactive materials such as silica- or phosphate-based glass materials with certain compositional modifiers that result in bioactivity, including but not limited to modifiers such as oxides of magnesium, sodium, potassium, calcium, phosphorus, and boron exhibit a narrow working range because the modifiers effectively reduce the devitrification temperature of the bioactive material .
  • the working range of a glass material is typically known to be the range of temperatures at which the material softens such that it can be readily formed. In a glass fiber forming process, the glass material in a billet or frit form is typically heated to a temperature in the working range upon which the glass material is molten and can be drawn or blown into a continuous or discontinuous fiber.
  • the working range of bioactive glass materials is inherently narrow since the devitrification temperature of the glass material is either extremely close or within the working range of the material .
  • the temperature at which a fiber can be drawn, blown, or otherwise formed is above the glass transition temperature but less than the devitrification temperature of the bioactive glass composition.
  • the molten or softened glass undergoes a phase change through crystallization that inhibits the continuous formation of fiber.
  • Fig. 5 depicts the method 200 of the present invention to fabricate the structural region 100 having a bioactive glass-ceramic composition.
  • amorphous glass fiber 210 is mixed with a binder 230, a pore former 240, and a liquid 250 to form a plastically moldable material which is then reaction formed into a glass-ceramic composition to form the porous structure.
  • a subsequent heat treating process is provided to continue the controlled crystallization of the porous structure into the desired glass- ceramic composition.
  • the fibers 210 can be provided in bulk form, or as chopped fibers in a composition that is a bioactive glass material.
  • a fiber 210 that is a bioactive glass material includes a fiber having a composition that is at least the components of the desired bioactive glass-ceramic composition.
  • the fiber 210 can be a silica calcium phosphate fiber, or it can be a silica calcium fiber, or a combination of any of the compositions used to form the desired bioactive glass-ceramic composition.
  • the diameter of the fiber 210 can range from about 1 to about 200 ⁇ and typically between about 5 to about 100 ⁇ .
  • Fibers 210 of this type can be produced with a relatively narrow and controlled distribution of fiber diameters or, depending upon the method used to fabricate the fiber, a relatively broad distribution of fiber diameters can be produced. Fibers 210 of a given diameter may be used or a mixture of fibers having a range of fiber diameters can be used. The diameter and length of the fibers 210 will influence the resulting pore size, pore size distribution, strength, and elastic modulus of the structural region 100, that will influence not only the osteoconducti vi ty of the structural region 100, but also the rate at which the porous structure is dissolved by body fluids when implanted in living tissue and the resulting strength characteristics, including compressive strength and elastic modulus.
  • the fibers 210 used according to the present invention as herein described are typically continuous and/or chopped glass fiber. As described herein above certain bioactive glass compositions are difficult to form as a fiber because the working range of the material is extremely narrow. Silica glass in various compositions can be readily drawn into continuous or discontinuous fiber but the addition of calcium oxide and/or phosphate compounds necessary to create a silica-based bioactive composition are the very compounds that result in the reduction of the working range of the silica-based glass.
  • a fiber 210 that has a composition that is a precursor to the desired bioactive glass-ceramic composition provides for a readily-obtained and easily formed fiber material to form a porous fiber- based structure that is crystallized into the desired bioactive composition during the formation of the tissue scaffold.
  • fiber 210 examples include silica-based glass fiber.
  • Silica-based materials having a calcium oxide content less than 30% by weight can be typically drawn or blown into fiber form.
  • Silica-based glass materials are generally required to have an alumina content less than 2% by weight since any amount of alumina in excess of that amount will reduce the bioactive characteristics of the resulting structure.
  • Phosphate glasses are precursors to bioactive
  • An exemplary method involves a combination of centrifugal spinning and gaseous attenuation. A glass stream of the appropriate viscosity flows continuously from a furnace onto a spinner plate rotating at thousands of revolutions per minute.
  • glass in a molten state is heated in a vessel perforated by one or more holes of a given diameter.
  • the molten glass flows and is drawn through these holes, forming individual fibers.
  • the fibers are merged into strands and collected on a mandrel.
  • a sol-gel fiber drawing method pulls or extrudes a sol-gel solution of the precursor with the appropriate viscosity into a fiber strand that is subsequently heat treated to bind the material into a cohesive fiber.
  • the sol-gel fiber can be formed from a precursor material or a combination of one or more precursor materials that react with each other to create the desired bioactive glass- ceramic composition at the reaction formation 330 step, as described in further detail below.
  • Yet other alternative methods can be used to provide a fiber 210.
  • whiskers and fiber-like segments of silica-based oxides of magnesium, sodium, potassium, calcium, and phosphorus can be provided as the fiber 210.
  • An organic binder material can be used as the binder 230, such as methylcellulose, hydroxypropyl
  • the binder 230 can include materials such as polyethylene, polypropylene, polybutene, polystyrene, polyvinyl acetate, polyester, isotactic polypropylene, atactic polypropylene, polysul phone , polyacetal polymers, polymethyl methacryl ate , f umaron-i ndane copolymer, ethylene vinyl acetate copolymer, styrene-butadi ene copolymer, acryl rubber, polyvinyl butyral , inomer resin, epoxy resin, nylon, phenol formaldehyde, phenol furfural, paraffin wax, wax emulsions,
  • polyethylene oxide polyacryl amides , polyethyterimi ne , agar, agarose, molasses, dextrines, starch, 1 i gnosul fonates , lignin liquor, sodium alginate, gum arabic, xanthan gum, gum tragacanth, gum karaya, locust bean gum, irish moss, scl erogl ucan , acrylics, and cationic gal actomanan , or combinations thereof.
  • binders 230 are listed above, it will be
  • the binder 230 provides the desired rheology and cohesive strength of the plastic batch material in order to form a desired object and maintaining the relative position of the fibers 210 in the mixture while the object is formed, while remaining inert with respect to the bioactive materials.
  • the physical properties of the binder 230 will influence the pore size and pore size distribution of the pore space 120 of the structural region 100.
  • the binder 230 is capable of thermal disintegration, or selective dissolution, without impacting the chemical composition of the bioactive components, including the fiber 210.
  • the liquid 250 is added as needed to attain a desired rheology in the plastic batch material suitable for forming the plastic batch material into the desired object in the subsequent forming step 270. Water is typically used though solvents of various types can be utilized. Rheological
  • Pore formers 240 are included in the mixture to define and enhance the pore space of the structural region 100 and to provide uniform heating throughout the object during the reaction formation step 330, as described in more detail below.
  • pore formers are non-reactive materials that occupy volume between the fibers in the plastic batch material during the mixing step 260 and the forming step 270.
  • the particle size and size distribution of the pore former 240 influences the resulting pore size and pore size distribution of the pore space in the structural region 100.
  • Particle sizes can typically range between about 25 ⁇ or less to about 450 ⁇ or more, or in the range of about 100 ⁇ to about 600 ⁇ , or
  • the particle size for the pore former can be a function of the fibers 210 diameter ranging from about 0.1 to about 100 times the diameter of the fibers 210.
  • the pore former 240 must be readily removable during the reaction forming step 330 without significantly disrupting the relative position of the surrounding fibers 210.
  • the pore former 240 can be removed via pyrolysis or thermal degradation, or volatilization at elevated temperatures during the reaction forming step 330.
  • graphite or carbon particles can be included in the mixture as the pore former 240.
  • Removal of the pore former during the reaction forming step 330 provides additional heat as the pore former 240 is exothermical ly oxidized or combusted so that a controlled heating of the glass fiber can facilitate the formation of the desired glass-ceramic composition and thus, the selection of the composition of at least a portion of the pore former 240 may be limited to those materials that provide the requisite temperature differential during heating, as described in further detail below.
  • One skilled in the art would appreciate the availability of alternate material compositions for use as the pore former 240. Additionally, mixtures of a plurality of materials and material compositions can be selected as a pore former 240.
  • Alternative materials include, without limitation: carbon black, activated carbon, graphite flakes, synthetic graphite, wood flour, modified starch, celluloses, coconut shell husks, latex spheres, bird seeds, saw dust, pyrolyzable polymers, poly (alkyl methacryl ate) , polymethyl methacryl ate , polyethyl methacryl ate , poly n-butyl methacryl ate , polyethers, poly
  • polystetrahydrof uran poly (1, 3- dioxolane), poly (alkalene oxides), polyethylene oxide, polypropylene oxide, methacrylate copolymers, polyisobutylene, polytrimethylene carbonate, polyethylene oxalate, polybeta-propiolactone , polydelta- val erol actone , polyethylene carbonate, polypropylene carbonate, vinyl tol uene/al pha-methyl styrene copolymer, styrene/al pha-methyl styrene copolymers, and ol ef i n-sul f ur dioxide copolymers.
  • Pore formers 240 may be generally defined as organic or inorganic, with the organic typically burning off at a lower temperature than the inorganic. Although several pore formers 240 are listed above, it will be appreciated that other pore formers 240 may be used. Pore formers 240 can be, though need not be, fully biocompatible since they are removed from the structural region 100 during processing.
  • additional precursors to the desired bioactive glass- ceramic material can be provided as a bonding agent 220 to combine with the composition of the fiber 210 to modify the composition of the glass and/or ceramic phase of the resulting material.
  • the bonding agent 220 can include powder-based material of the same composition as the bulk fiber 210, or it can include powder-based material of a different composition.
  • the bonding agent 220 can be coated on the fibers 210 as a sizing or coating.
  • additional precursors to the bioactive composition are added to the fiber, for example, as a sizing or coating.
  • the bonding agent 220 is a sizing or coating that is added to the fiber during or prior to the mixing step 260.
  • the bonding agent 220 can be solids dissolved in a solvent or liquid that are deposited on the fiber and/or other bonding agent 220 precursors when the liquid or solvent is removed.
  • the relative quantities of the fiber 210 and the bonding agent 220 combined with the heat treatment generally determine the compositions of the respective phases of glass and ceramic components of the structural region 100.
  • the relative quantities of the respective materials, including the bulk fiber 210, the binder 230, and the liquid 250 depend on the overall porosity desired in the structural region 100.
  • nonvolatile components 275 such as the fiber 210
  • the relative quantity of volatile components 285, such as the binder 230 and the liquid 250 would amount to approximately 60% of the mixture by volume, with the relative quantity of binder to liquid determined by the desired rheology of the mixture.
  • the amount of the volatile components 285 is adjusted to include the volatile pore former 240.
  • the amount of the nonvolatile components 275 would be adjusted to include the nonvolatile bonding agent 220. It can be appreciated that the relative quantities of the nonvolatile components 275 and volatile components 285 and the resulting porosity of the structure 100 will vary as the material density may vary due to the reaction of the components during the reaction forming step 330.
  • the fiber 210, the binder 230, the liquid 250, the pore former 240 and optionally, the bonding agent 220, if included, are mixed into a homogeneous mass of a plastically deformable and uniform mixture.
  • the mixing step 260 may include dry mixing, wet mixing, shear mixing, and kneading, which can be necessary to evenly distribute the material into a homogeneous mass while imparting the requisite shear forces to break up and distribute or de-agglomerate the fibers 210 with the non- fiber materials.
  • the amount of mixing, shearing, and kneading, and duration of such mixing processes depends on the selection of fibers 210 and non-fiber materials, along with the selection of the type of mixing equipment used during the mixing step 260, in order to obtain a uniform and consistent distribution of the materials within the mixture, with the desired
  • the kneading element of the mixing step 260 distributes the fiber 210 with the bonding agent 220 and the binder 230 to provide a formable batch of a homogeneous mass with the fiber being arranged in an overlapping and intertangled relationship with the remaining fiber in the batch.
  • the forming step 270 forms the mixture from the mixing step 260 into the object that will become the structural region 100.
  • the forming step 270 can include extrusion, rolling, pressure casting, or shaping into nearly any desired form in order to provide a roughly shaped object that can be cured in the reaction forming step 330 to provide the structure 100. It can be appreciated that the final dimensions of the structure 100 may be different than the formed object at the forming step 270, due to expected shrinkage of the object during the reaction forming step 330, and further machining and final shaping may be necessary to meet specified dimensional requirements.
  • the forming step 270 extrudes the mixture into a cylindrical rod using a piston extruder forcing the mixture through a round die.
  • the object is then reaction formed into the glass-ceramic composition at reaction forming step 330.
  • the object is subjected to a series of heat treatments that sequentially remove the volatile components 285 without substantially disturbing the relative position of the fiber 210, as
  • the mixing step 260 determines whether the mixing step 260, the forming step 270 and the volatile components 285 including the pore former 240, and bond the fiber into a porous construct and initiating a reaction formation of the bioactive glass fiber composition into a bioactive glass-ceramic composition to provide the structural region 100.
  • the reaction forming step can include a drying phase to remove the liquid in an elevated temperature environment with or without forced convection.
  • Various methods of heating the object can be used to dry the parts including, but not limited to heated air convection heating, vacuum freeze drying, solvent extraction, microwave or electromagnetic radio frequency (RF) drying methods.
  • the liquid 250 within the formed object is preferably not removed so rapidly so as to contribute to cracks from shrinkage.
  • the formed object can be dried when exposed to temperatures between about 90°C and 150°C for about one hour, though the actual drying time may vary due to the size and shape of the formed object, with larger more massive objects taking longer to dry.
  • the liquid itself, and/or other components of the object absorb the radiated energy to more evenly generate heat throughout the material During the drying phase of the reaction forming step 330, depending on the selection of materials used as the volatile components 285, the binder 230 can congeal or gel to provide greater green strength to provide rigidity and strength in the object for subsequent handl i ng .
  • the reaction forming step 330 can include a binder removal to remove the binder 230 through pyrolysis, solvent extraction, and/or thermal degradation.
  • HPMC used as a binder 230 will thermally decompose at approximately 300°C and a heat treatment phase holding a formed object at that temperature for approximately two hours can effectively remove the HPMC binder without disturbing the relative position of the fibers 210 in the formed object.
  • the reaction formation step 330 includes a bond formation phase that heats the formed object to a reaction and bond formation temperature resulting in the formation of fiber-to-fiber bonds at overlapping and adjacent nodes of the fiber structure.
  • the temperature at which the reaction and bond formation temperature occurs exceeds the devitrification temperature of the glass composition of the fiber 210 so that a glass-ceramic composition is formed.
  • the tendency of an amorphous glass composition to crystalize depends largely on glass
  • an amorphous glass such as silica calcium phosphate 13-93, will precipitate wollastonite (CaSi03) crystals at temperatures above 800°C when the glass is in a high surface area to mass relationship such as the fiber construct of the formed object.
  • the bond formation phase of the reaction formation step 330 is preferably performed using a combustion of the pore former 240 to provide rapid and uniform heating throughout the volume of the formed object.
  • the combustion of the pore former 240 in conjunction with the thermal environment during the reaction formation step 330 provides the thermal energy necessary to crystallize the fiber 210 into the desired glass-ceramic composition homogeneously throughout the internal structure of the formed object.
  • greater than 50% by weight of the porous matrix is a single phase of a calcium silicate ceramic.
  • greater than 40% by weight of the porous matrix is a single phase of a calcium silicate ceramic.
  • greater than 20% by weight of the porous matrix is a single phase of a calcium silicate ceramic.
  • the combustion of the pore former 240 is one mechanism to provide the heating rate to initiate the formation of the glass ceramic by providing rapid and uniform heating throughout the formed object during the reaction formation step 330.
  • the pore former 240 is preferably a combustible material such as carbon or graphite, starch, organics or polymers such as polymethyl methacrylate (PMMA) , or other material that exothermi cal ly oxidizes.
  • the pore former 240 is selected based on the temperature at which the material initiates combustion as can be determined by thermal analysis such as Thermogravimetri c Analysis (TGA) or Differential Thermal Analysis (DTA) or a simultaneous combination of DTA/TGA which detects both mass loss and thermal response.
  • TGA Thermogravimetri c Analysis
  • DTA Differential Thermal Analysis
  • a simultaneous combination of DTA/TGA which detects both mass loss and thermal response.
  • a DTA/TGA analysis determines the exothermic combustion point of carbon particles to be 621°C and graphite flakes to be 603°C that is suitable for use with a 13-93 bioactive glass composition having a devitrification temperature of approximately 800°C.
  • the reaction formation step 330 provides thermal environment sufficient to convert the amorphous glass composition of the fiber 210 into a glass- ceramic composition uniformly throughout the formed body through convective heat transfer from the kiln or oven in combination with a second heating source such as the exothermic combustion of the pore former 240 and holding at a temperature exceeding the devitrification temperature of the amorphous glass composition.
  • a second heating source such as the exothermic combustion of the pore former 240 and holding at a temperature exceeding the devitrification temperature of the amorphous glass composition.
  • the glass transition temperature of the amorphous glass fiber is typically exceeded during the reaction formation step 330 as the overlapping and intertangled fiber is fused into a porous rigid matrix with the distinct structural features of the fiber material becoming diminished. As the crystalline phase precipitates the amorphous glass fuses to form the porous rigid matrix.
  • the fiber form of the bioactive glass provides
  • Additional control over the reaction formation step 330 can be provided through controlling the heating rate of process gas in the kiln or oven to delay or accelerate the combustion of the pore former 240.
  • air or nitrogen purge flowrates can be adjusted to control the amount of oxygen present in the processing environment to support combustion or oxidation of the pore former materials.
  • Alternative heating modes for the kiln can include microwave heating and/or direct flame heating to provide the heating rates necessary to initiate crystallization of the ceramic phase of the porous matri x .
  • the bonds formed between overlapping and adjacent nodes of the fibers forming the formed object can be glass bonds having a composition
  • the bonds can also have the same glass-ceramic composition that forms during the reaction formation step 330.
  • the present invention provides a bioactive and resorbable tissue scaffold device that can be fabricated using medically approved materials or fabricated into medically approved materials.
  • an optional heat treating step 335 is performed subsequent to the reaction formation step 330 to remove internal stress in the structure and to promote crystal growth of the ceramic phase of the glass-ceramic composition.
  • the heat treating step 335 can be performed by heating the formed object after the reaction formation step 330 to a temperature at which the glass-ceramic material will support continued growth of the ceramic phase, such as when heated above the devitrification temperature of the composition of the amorphous glass fiber. Additionally, the heat treating step 335 can relieve internal stresses that may build up during the heating/cooling cycles in the reaction formation step 330.
  • Heat treating the glass-ceramic material of the formed object after the reaction formation step 330 involves heating the object to a temperature that is the stress relief point of the materials, i.e., a temperature at which the glass- ceramic material is hard enough to maintain its shape and form but sufficient to relieve internal stress.
  • the heat treating temperature is determined by the composition of the glass-ceramic material.
  • the duration of the heat treating step 335 is determined by the relative size and mass of the object.
  • the heat treating step 335 includes a cooling phase that slowly cools the heat treated object at a rate that is limited by the heat capacity, thermal conductivity, and thermal expansion coefficient of the glass-ceramic material.
  • most glass-ceramic compositions having a mass of approximately 10 grams can be heat treated in a kiln at a temperature that is approximately 50°C less than the reaction formation temperature for four to six hours and cooled to room temperature over approximately four hours.
  • the structural region 100 can be composed of an amorphous bioactive glass composition in high strength / lower porosity form that exhibits strength sufficient to support anatomic loads in the human spine.
  • the structural region 100 in a bioactive glass composition can be fabricated using the same method 200 described above with reference to the first exemplary embodiment of Fig. 1 with specific modifications to the process to ensure the formed object maintains the amorphous glass composition of the bioactive fiber 200.
  • a first modification to the process of the method 200 can be implemented by reducing or eliminating the use of a poreformer 240 that exhibits an exothermic reaction so as to avoid thermal excursions at or exceeding the devitrification temperature of the composition of the bioactive glass of the fiber 210 and/or any bonding agents 220.
  • the bioactivity of the fiber 210 and/or any bonding agents 220 maintained in an amorphous form will exhibit greater bioactivity, i.e., increased rate of resorption when implanted, to permit bone tissue ingrowth through the structural region 100 that can be offset by the reduction in porosity and/or a reduction in a pore size in the region.
  • the bioactivity of the structural region 100 as determined by the compositional bioactivity and the pore morphology of the material must maintain the intervertebral space until such time as fusion between the vertebra occurs.
  • the structural region 100 in a bioactive glass composition having porosity in the range that provides sufficient strength when implanted and strength retention during fusion can be fabricated through various other modifications of the method 200 described above with reference to the glass- ceramic exemplary embodiment of Fig. 1.
  • the porosity is controlled through variation of controllable variables including the diameter and length of the fiber 210, the relative quantity and particle size of the bonding agent 220, the relative quantity of the binder 230, and the particle size and quantity of the pore former 240.
  • processing variables such as heating rate, temperature, and duration can influence the resulting porosity of the formed object during the method 200.
  • the bonding agent 220 can be eliminated and/or the mixing parameters such as time and speed can be increased to further chop the fibers to reduce the distribution of fiber length in the mixture.
  • the reduction of porosity of the structural region 100 in a bioactive glass composition to provide high strength is attained through an extended duration in the reaction formation step 330 to densify the porous structure once the fiber bonds are formed.
  • the formed object of the glass-ceramic or glass composition is machined into a shape having dimensions sufficient to maintain the intervertebral space once implanted to form a first spinal interbody device 10.
  • the first spinal interbody device 10 can include a central cavity 20 into which autograft or allograft can be inserted during the operational procedure implanting the intervertebral device 10.
  • a second spinal interbody device 30 is shown for use in fusion of adjacent vertebrae to maintain the intervertebral spacing as bone tissue fuses the adjacent vertebrae.
  • the structural region 100 of the first spinal interbody device 10 according to Fig. 1 is used with the central cavity 20 of the first spinal interbody device 10 in either of a bioactive glass or a glass-ceramic composition filled with a porous bioactive glass region 40.
  • the porous bioactive glass region 40 has an increased level of bioactivity compared to the bioactivity of the structural region 100 due to the bioactivity of amorphous bioactive glass and/or increased porosity relative to the structural region 100.
  • the porous bioactive glass region 40 of the second exemplary embodiment can be fabricated using the same method 200 described above with reference to the first exemplary embodiment of Fig. 1 with specific modifications to the process to ensure the formed object maintains the amorphous glass composition of the bioactive fiber 200.
  • a first modification to the process of the method 200 can be implemented by reducing or eliminating the use of a pore former 240 that exhibits an exothermic reaction so as to avoid thermal excursions at or exceeding the devitrification temperature of the composition of the bioactive glass of the fiber 210 and/or any bonding agents 220.
  • bioactivity of the fiber 210 and/or any bonding agents 220 maintained in an amorphous form will exhibit greater bioactivity, i.e. , increased rate of resorption when implanted, to permit bone tissue ingrowth through the space occupied by the porous bioactive glass region 40. This accelerated ingrowth will effectuate fusion of the adjacent vertebrae before the structural region 100 is resorbed, thereby permitting the structural region to provide load bearing support and maintain the intervertebral spacing until such time that fusion has occurred.
  • the porous bioactive region provides a similar function as autograft without the need to harvest the graft tissue, or allograft without the complications and potential risks of using cadaver tissue.
  • the porous bioactive glass region 40 can be fabricated as a formed object in a process as disclosed above and then machined into a shape that is inserted into a central cavity of the structural region 100.
  • the porous bioactive glass region 40 can be fabricated by creating a plastic mixture of the batch material as disclosed above that is pressed into the central cavity of the structural region that is then heat treated to form a rigid amorphous porous structure, followed by machining, if necessary, to remove excess material to provide a rigid form adhered and contained within the region 40.
  • the second exemplary embodiment can be adapted to provide a structural region 100 in the central cavity of the interbody device 30 with the porous region 40 in the outer peripheral region of the interbody device 30. In this embodiment the porous region 40 will resorb and stimulate ingrowth between opposing vertebral bodies more rapidly than the central region to effectuate fusion of the adjacent vertebrae .
  • a third spinal interbody device 50 is shown for use in fusion of adjacent vertebrae to maintain the intervertebral spacing as bone tissue fuses the adjacent vertebrae.
  • a structural region 100 is formed with a central cavity in a bioactive glass or glass-ceramic composition as disclosed above according to the method 100 described with reference to the embodiments of Fig. 1.
  • a plastic batch mixture of the same, or similar composition of bioactive fiber 210 is created according to the method 100 described above with the selection of pore former 240 being made so as to reduce or eliminate the potential for an exothermic reaction during pore former removal so as to maintain the amorphous form of the fiber 210 and/or any bonding agent 220.
  • the plastic batch material is then applied to the exterior circumferential face of the structural region 100 and then cured to form a porous bioactive glass outer region 60.
  • porous bioactive glass outer region 60 of the third exemplary embodiment is cured into a rigid form and adhered to the exterior
  • the bioactivity of the fiber 210 and/or any bonding agents 220 when in its original amorphous form will exhibit a comparatively higher level of bioactivity and thus resorb by the body at a faster rate than the glass ceramic composition of the structural region or the low porosity form of the structural region having a bioactive glass composition and thus, advance tissue ingrowth around the exterior circumferential region of the implant, thereby promoting fusion of the adjacent vertebrae while the structural region 100 can continue to maintain the intervertebral spacing and address load bearing forces.
  • the central cavity 20 can be empty or filled with autograft, allograft, or other synthetic bone graft materials to promote fusion through tissue i ngrowth .
  • a fourth spinal interbody device 70 is shown for use in fusion of adjacent vertebrae to maintain the intervertebral spacing as bone tissue fuses the adjacent vertebrae.
  • the spinal third spinal interbody device 50 with a porous bioactive glass outer region 60 as disclosed with reference to Fig. 3 is used with the bioactive glass region 40 in the central cavity of the structural region 100 as disclosed above with reference to Fig. 2.
  • the high level of bioactivity of the bioactive glass region 40 and the bioactive glass outer region 60 of the fourth spinal intervertebral device 70 will promote bone tissue ingrowth through the central cavity of the structural region 100 and advance tissue ingrowth around the exterior circumferential region of the implant.
  • the fourth spinal interbody device 70 can effectuate fusion of the adjacent vertebrae while the structural region 100, with its comparatively lower level of bioactivity and/or lower porosity through reduced pore size and i nterconnectedness , and thus resorption, will continue to provide load bearing support and maintain the intervertebral spacing wile the bone matures into healthy and mature bone tissue for a safe and effective fusion.
  • the implant 600 has a first end surface 630 at a proximal end and a second end surface 640 at a distal end of the body with a body height 620.
  • the implant 600 has a body wall 610 and a central cavity 650 extending from the first surface 630 to the second surface 640.
  • a structural region can be provided that extends from the first surface 630 to the second surface 640 and a porous region from the first surface 630 to the second surface 640, each of the structural region and the porous region will resorb, albeit relatively slowly, with mature bone maintaining the intervertebral space and load, leaving a fused vertebrae with no trace of the implant 600.
  • the first spinal interbody device 10 can be fabricated as follows. 100 grams of silica calcium phosphate glass fiber in an amorphous composition generally known as 13-93 in chopped form having an average diameter of 30 ⁇ is mixed with 25 grams HPMC as the binder 230, 75 grams PMMA having a particle size resulting from sieving in a 30-50 mesh (297 ⁇ ⁇ ⁇ -595 ⁇ ⁇ ⁇ ) and 12.5 grams graphite powder having a particle size resulting from sieving in a 40-100 mesh (149 ⁇ -400 ⁇ ) , collectively as the pore former, 12.5 grams 13-93 glass material finely ground in powder form as a bonding agent 220, and 100 ml water.
  • the dried block is then subjected to heat treatment raising to 900°C for 30 minutes.
  • the graphite pore former is observed to burn out to rapidly increase the internal temperature of the block during the heat treatment cycle to promote the formation of a wollastonite in a glass-ceramic composition.
  • the block is then machined into the shape 600 as shown in Fig. 6 and then heat treated at 720°C for 10 hours to promote further crystallization of the structural region and exhibiting a porosity of approximately 55% with a compressive strength of about 55MPa.
  • the first spinal interbody device 10 can alternatively be fabricated as follows.
  • a porous bioactive material having an amorphous composition is fabricated by mixing 100 grams of chopped 13-93 fiber having a diameter of 30 ⁇ with 25 grams HPMC as the binder, 50 grams PMMA having a particle size resulting from sieving in a 40-50 mesh as the pore former, 12.5 grams 13-93 glass material as the bonding agent with 90 ml water, into a homogeneous mixture.
  • the homogeneous mixture is then formed into a block and heat treated by raising the temperature to 660°C for 2 hours with 10 SCFH air flow to form a porous amorphous bioactive glass material.
  • the block is then machined into the shape 600 as shown in Fig. 6.
  • the porous bioactive material will exhibit a porosity of approximately 45% with a compressive strength of about 35MPa.
  • the second spinal interbody device 30 can be fabricated as follows.
  • a porous bioactive material having an amorphous composition is fabricated by mixing 100 grams of chopped 13-93 fiber having a diameter of 30 ⁇ with 25 grams HPMC as the binder, 50 grams PMMA having a particle size resulting from sieving in a 40-50 mesh as the pore former, 12.5 grams 13-93 glass material as the bonding agent with 90 ml water, into a homogeneous mixture.
  • the homogeneous mixture is then formed into a block and heat treated by raising the temperature to 650°C for 1.5 hours with 10 SCFH air flow to form a porous amorphous bioactive glass material.
  • the amorphous material 40 in this example has a porosity of about 59% with a compressive strength of 12 MPa.
  • the third spinal interbody device 50 can be fabricated as follows. A first spinal interbody device 10 in the glass-ceramic or alternative amorphous composition is provided with approximately 20% of the outer circumferential material removed by machining. The homogeneous mixture of the second interbody device 30 is then spread to form an outer layer and then heat treated by raising the temperature to 650°C for 1.5 hours with 10 SCFH air flow to form a porous amorphous bioactive glass material on the outer circumferential surface of the device. The first spinal interbody device 10 can be placed centrally in a cylinder with the homogeneous mixture pressed in to surround the device. Once dried and heat treated in accordance with the procedure above with reference to the porous amorphous glass material of the second spinal interbody device 30 above, the third spinal interbody device 50 is provided. A final machining process can be performed to remove excess material using the central cavity for orientation.
  • the fourth spinal interbody device 70 can be fabricated as follows. The the porous amorphous glass material machined into the shape of the central cavity, as disclosed above with reference to the second spinal interbody device 30 above is inserted into the central cavity of the third spinal interbody device 50 as described above. A final machining step can be performed to remove any excess material.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne un dispositif intervertébral fabriqué en matériaux de verre bioactifs complètement résorbables, qui est utilisé pour maintenir un écartement intervertébral dans la fusion de vertèbres adjacentes. Le dispositif intervertébral peut comprendre des régions de matériau poreux présentant des niveaux variés de bioactivité de telle sorte que la fusion par l'intermédiaire d'une interposition de tissu osseux peut s'effectuer pendant que des régions du dispositif intervertébral peuvent continuer à maintenir l'écartement intervertébral.
PCT/US2014/048411 2013-08-02 2014-07-28 Dispositif intervertébral résorbable WO2015017324A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361861793P 2013-08-02 2013-08-02
US61/861,793 2013-08-02

Publications (1)

Publication Number Publication Date
WO2015017324A1 true WO2015017324A1 (fr) 2015-02-05

Family

ID=52432360

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/048411 WO2015017324A1 (fr) 2013-08-02 2014-07-28 Dispositif intervertébral résorbable

Country Status (1)

Country Link
WO (1) WO2015017324A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106729977A (zh) * 2017-01-12 2017-05-31 上海锐植医疗器械有限公司 一种生物活性椎间融合器
EP3607914A1 (fr) * 2018-08-09 2020-02-12 Stryker European Holdings I, LLC Implants intervertébraux et leurs caractéristiques d'optimisation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149688A (en) * 1995-06-07 2000-11-21 Surgical Dynamics, Inc. Artificial bone graft implant
US6240926B1 (en) * 1996-08-08 2001-06-05 The Trustees Of The University Of Pennsylvania Compositions and methods for intervertebral disc reformation
US6696073B2 (en) * 1999-02-23 2004-02-24 Osteotech, Inc. Shaped load-bearing osteoimplant and methods of making same
WO2004098456A2 (fr) * 2003-05-01 2004-11-18 Therics, Inc. Biostructure poreuse partiellement remplie par interpenetration et procede de fabrication
US7767221B2 (en) * 2004-03-05 2010-08-03 The Trustees Of Columbia University In The City Of New York Multi-phased, biodegradable and osteointegrative composite scaffold for biological fixation of musculoskeletal soft tissue to bone

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149688A (en) * 1995-06-07 2000-11-21 Surgical Dynamics, Inc. Artificial bone graft implant
US6240926B1 (en) * 1996-08-08 2001-06-05 The Trustees Of The University Of Pennsylvania Compositions and methods for intervertebral disc reformation
US6696073B2 (en) * 1999-02-23 2004-02-24 Osteotech, Inc. Shaped load-bearing osteoimplant and methods of making same
WO2004098456A2 (fr) * 2003-05-01 2004-11-18 Therics, Inc. Biostructure poreuse partiellement remplie par interpenetration et procede de fabrication
US7767221B2 (en) * 2004-03-05 2010-08-03 The Trustees Of Columbia University In The City Of New York Multi-phased, biodegradable and osteointegrative composite scaffold for biological fixation of musculoskeletal soft tissue to bone

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106729977A (zh) * 2017-01-12 2017-05-31 上海锐植医疗器械有限公司 一种生物活性椎间融合器
EP3607914A1 (fr) * 2018-08-09 2020-02-12 Stryker European Holdings I, LLC Implants intervertébraux et leurs caractéristiques d'optimisation
US11065126B2 (en) 2018-08-09 2021-07-20 Stryker European Operations Holdings Llc Interbody implants and optimization features thereof
US11857430B2 (en) 2018-08-09 2024-01-02 Stryker European Operations Holdings Llc Interbody implants and optimization features thereof
US12263091B2 (en) 2018-08-09 2025-04-01 Stryker European Operations Holdings Llc Interbody implants and optimization features thereof

Similar Documents

Publication Publication Date Title
US9968463B2 (en) Devices and methods for tissue engineering
US9775721B2 (en) Resorbable interbody device
US20110206828A1 (en) Devices and Methods for Tissue Engineering
US20120219635A1 (en) Devices and Methods for Tissue Engineering
EP2663343B1 (fr) Dispositifs et procédés d'ingénierie tissulaire
US20140050765A1 (en) Devices and Methods for Tissue Engineering
WO2015017324A1 (fr) Dispositif intervertébral résorbable
US9066998B2 (en) Devices and method for tissue engineering

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14832299

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14832299

Country of ref document: EP

Kind code of ref document: A1